Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 11 12 13 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Curexsys–Sartorius: investment, 202012 seed financing round totalling €8.2m incl Sartorius acquiring 21% equity stake 2020-12-09
Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius 2020-12-09
Novartis–RetinAI Medical: AI-based image analysis, 202012– collab expansion master agreement using RetinAI Discovery platform in ophthalmology 2020-12-08
RetinAI Medical–Charles Consultants: public relations, 202012 service existent by Sue Charles 2020-12-08
Biomes NGS–GPS Ventures: investment, 202012 pre-series A investment €2m from GPS Ventures GmbH 2020-12-07
Boehringer–Proxygen: molecular glue degraders, 202012– collab + license agreem developm in combi with PROTACs against oncogenic targets 2020-12-07
Mosa Meat–SEVERAL: investment, 202012 financing round Series B 2nd closing $20m bringing total Series B to $75m 2020-12-07
Bayer–Atara Biotherapeutics: cell therapy, 202012–202209 collab + ww license $60m upfront + $610m milestones CAR T-cell therapies TERMINATED 9/22 2020-12-06
MaaT Pharma–Céleste Management: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor Céleste Management 2020-12-01
MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m 2020-12-01
MaaT Pharma–SkyViews Life Science: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor SkyViews Life Science 2020-12-01
Noema Pharma–SEVERAL: investment, 202012 financing round Series A CHF54m ($59m) co-led by Sofinnova Partners + Polaris Partners 2020-12-01
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
Adrenomed–HBM: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor HBM Healthcare Investments 2020-11-30
Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM 2020-11-30
Adrenomed–Wellington Partners: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor Wellington Partners 2020-11-30
Perfood–Boehringer: investment, 202011 financing round Series A totalling €5m incl lead investor Boehringer Ingelheim Venture Fund 2020-11-30
Perfood–SEVERAL: investment, 202011 financing round Series A €5m led by Boehringer Ingelheim Venture Fund 2020-11-30
Perfood–UV-Cap: investment, 202011 financing round Series A totalling €5m incl co-investor UV-Cap 2020-11-30
Perfood–Verve Capital Partners: investment, 202011 financing round Series A totalling €5m incl co-investor investiere 2020-11-30
Kadans Science Partner–Axa: investment, 202011–202012 acquisition €500m by Axa IM Real Assets on behalf of clients from Oaktree Capital Management 2020-11-26
BioNTech–InstaDeep: AI-based drug discovery, 2019– collab initiated in 2019 2020-11-25
BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies 2020-11-25
Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF 2020-11-25
Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF 2020-11-25
Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund 2020-11-25
Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG 2020-11-25
Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund 2020-11-25
Emphysys–Paramit: investment, 202011 acquisition of Emphysis Inc by Paramit Corp 2020-11-24
Atai Life Sciences–SEVERAL: investment, 202011 financing round Series C $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio 2020-11-23
Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund 2020-11-23
Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo 2020-11-23
Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund 2020-11-23
Relief Therapeutics–GEM Global Yield: investment, 202011 existent majority shareholder owning 51.38% of capital + voting rights 2020-11-19
SynOx Therapeutics–Roche: emactuzumab, 202011 excl ww rights for developm + production + commercialisation 2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
Pharvaris–Bain Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Bain Capital Life Sciences 2020-11-18
Pharvaris–Cormorant Asset Management: investment, 202011 financing round Series C totalling $80m incl new + co-investor Cormorant Asset Management 2020-11-18
Pharvaris–Foresite Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Foresite Capital 2020-11-18
Pharvaris–General Atlantic: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor General Atlantic 2020-11-18
Pharvaris–Rockefeller: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Venrock Health Capital Partners 2020-11-18
Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic 2020-11-18
Pharvaris–VenBio: investment, 202011 financing round Series C totalling $80m incl existing + co-investor venBio Partners 2020-11-18
Pharvaris–Viking Global Investors: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor Viking Global Investors 2020-11-18
Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties 2020-11-16
Start Codon–Novartis: investment, 202011 closing of Start Codon Fund I LP totalling £15m incl LP Novartis International AG 2020-11-16
Start Codon–SEVERAL: investment, 202011 closing of Start Codon Fund I LP at £15m incl LPs Novartis International AG + Cambridge Innovation Capital 2020-11-16
m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences 2020-11-12
Metagenomi–Agent Capital: investment, 202011 financing round Series A totalling $65m incl co-investor Agent Capital 2020-11-12
Metagenomi–Bayer: investment, 202011 financing round Series A totalling $65m incl co-lead investor Leaps by Bayer 2020-11-12
Metagenomi–HOF Capital: investment, 202011 financing round Series A totalling $65m incl co-investor HOF Capital 2020-11-12
Metagenomi–Humboldt Fund: investment, 202011 financing round Series A totalling $65m incl co-lead investor Humboldt Fund 2020-11-12
Metagenomi–InCube Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor InCube Ventures 2020-11-12
Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund 2020-11-12
Metagenomi–Sozo Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor Sozo Ventures 2020-11-12
Synendos Therapeutics–Bernina BioInvest: investment, 202011 financing round Series A totalling CHF20m incl co-investor Bernina BioInvest 2020-11-12
Synendos Therapeutics–Essential Investments: investment, 202011 financing round Series A totalling CHF20m incl co-investor Essential Investments 2020-11-12
Synendos Therapeutics–High-Tech Gründerfonds: investment, 202011 financing round Series A totalling CHF20m incl co-investor HTGF 2020-11-12
Synendos Therapeutics–Kurma: investment, 202011 financing round Series A totalling CHF20m incl co-lead investor Kurma Partners 2020-11-12
Synendos Therapeutics–Lichtsteiner Foundation: investment, 202011 financing round Series A totalling CHF20m incl co-investor Lichtsteiner Foundation 2020-11-12
Synendos Therapeutics–Optimum Strategic Communications: public relations, 202011 service existent by Optimum 2020-11-12
Synendos Therapeutics–OTHER: investment, 202011 financing round Series A totalling CHF20m incl private co-investors 2020-11-12
Synendos Therapeutics–Schroders: investment, 202011 financing round Series A totalling CHF20m incl co-investor Schroder Adveq 2020-11-12
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
Synendos Therapeutics–Sunstone Life Science: investment, 202011 financing round Series A totalling CHF20m incl co-lead investor Sunstone LSV 2020-11-12
Synendos Therapeutics–Zürcher Kantonalbank: investment, 202011 financing round Series A totalling CHF20m incl co-investor ZKB 2020-11-12
MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets 2020-11-11
Catalym–Bavaria (govt): investment, 202011 financing round Series B totalling €50m incl new + co-investor Wachstumsfonds Bayern 2020-11-10
Catalym–BioGeneration Ventures: investment, 202011 financing round Series B totalling €50m incl existing + co-investor BGV 2020-11-10
Catalym–Forbion: investment, 202011 financing round Series B totalling €50m incl existing + co-investor Forbion 2020-11-10
Catalym–Germany (govt): investment, 202011 financing round Series B totalling €50m incl new + co-investor Coparion 2020-11-10
Catalym–MC Services: public relations, 202011 service existent by MC Services 2020-11-10
Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl new + co-investor Novartis Venture Fund 2020-11-10
Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III 2020-11-10
Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl new + lead investor Vesalius Biocapital III 2020-11-10
Roche–Cevec: cell line technology, 202011– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies 2020-11-10
Apeiron–Domainex: drug discovery services, 202011– collab expansion supply of lead optimisation services for Cbl-b targeting APN431 compound series 2020-11-09
Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties 2020-11-09
Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept 2020-11-09
Memo Therapeutics–Bernina BioInvest: investment, 202011 financing round Series B totalling CHF14m incl new + co-investor Bernina BioInvest 2020-11-05
Memo Therapeutics–Halsin Partners: public relations, 202011 service existent by Halsin Partners 2020-11-05
Memo Therapeutics–Jaquet Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Jaquet Partners 2020-11-05
Memo Therapeutics–OTHER: investment, 202011 financing round Series B totalling CHF14m incl new private investors 2020-11-05
Memo Therapeutics–Redalpine: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Redalpine 2020-11-05
Memo Therapeutics–Schroders: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Schroder Adveq 2020-11-05
Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB 2020-11-05
Memo Therapeutics–Verve Capital Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Investiere 2020-11-05
Memo Therapeutics–Zürcher Kantonalbank: investment, 202011 financing round Series B totalling CHF14m incl existing + lead investor Swisscanto by ZKB 2020-11-05
Corlieve Therapeutics–Bellevue: investment, 202011 seed financing round incl co-investor Pureos Bioventures 2020-11-02
Corlieve Therapeutics–Eurazeo: investment, 202011 seed financing round incl co-lead investor IDinvest Partners 2020-11-02
Corlieve Therapeutics–Kurma: investment, 202011 seed financing round incl co-lead investor Kurma Partners 2020-11-02
Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures 2020-11-02
Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) 2020-11-02
Polaris Science (SG)–Nynomic: plant phenotyping, 202011– distribution in Singapore + Malaysia of LemnaTec solutions for phenotyping + seed testing 2020-11-01
Molecular Partners–Novartis: investment, 202010 acquisition CHF40m ordinary shares at CHF23/share by Novartis resulting in 6% shareholding 2020-10-28
Novartis–Molecular Partners: DARPins, 202010– license option + collab CHF20m upfront + CHF150m milestones + royalties developm DARPins for COVID-19 2020-10-28
Sidekick Health–SEVERAL: investment, 202010 financing round Series A $20m led by Wellington Partners + Asabys Partners 2020-10-28
TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly 2020-10-27
TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund 2020-10-27
TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly 2020-10-27
next pagenext page 1 2 3 ... 11 12 13 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] Fighting Customers 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top